Neumora Therapeutics, Inc. Common Stock (NMRA)
Oxford Ledge is still expanding full research coverage of NMRA. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Neumora develops brain-penetrant medicines for neuropsychiatric and neurodegenerative disorders, with its lead candidate in Phase 3 trials for depression.
SEC filings
- 8-K Entry into material agreement; Creation of direct financial obligation; Costs for exit or disposal activities; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-15
- 8-K Shareholder vote results 2026-05-29
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-07
- DEF 14A Proxy statement for shareholder vote 2026-04-17
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for NMRA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NMRA in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.